PublicationsNewslettersSubscribe to our newsletterSubscribe to our newsletters CommentsThis field is for validation purposes and should be left unchanged. This iframe contains the logic required to handle AJAX powered Gravity Forms. Volume #2Issue 4: Agenus’ Next-Gen anti-CTLA-4 (AGEN1181) - Can this be a breakthrough cancer treatment?Issue 3: Biotech Electronic Security Token (BEST) Innovation and BenefitsIssue 1: Vision 2019 A Special EditorialIssue 2: Agenus’ First Biotech Electronic Security Token (BEST)Volume #1Issue 12: Agenus & Gilead to Collaborate in a $150M Upfront TransactionIssue 11: 2018 Year in ReviewIssue 10: Agenus Presents at SITC 2018Issue 9: Agenus’ Novel Cancer Vaccine Platform: PhosphoSynVax™ (PSV™)Issue 8: Agenus’ CTLA-4 and PD-1 Antibodies Show Clinical BenefitIssue 7: Innovation and Speed in Antibody DiscoveryIssue 6: Agenus Enabling PartnersIssue 5: Innovation Is Key To Outpacing ObsolescenceIssue 4: Delivering Innovation with SpeedIssue 3: Targeting Cancers with Agenus’ Proprietary CombinationsIssue 2: Agenus NexGen Neoantigen Vaccines Advance in Clinical Trials to CombinationsIssue 1: Update on Clinical Trials
